Oral Administration System Based on Meloxicam Nanocrystals: Decreased Dose Due to High Bioavailability Attenuates Risk of Gastrointestinal Side Effects

• Main Authors: Noriaki Nagai (Author), Fumihiko Ogata (Author), Hiroko Otake (Author), Naohito Kawasaki (Author)
• Format: Book
• Published: MDPI AG, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Meloxicam (MLX) is widely applied as a therapy for rheumatoid arthritis (RA); however, it takes far too long to reach its peak plasma concentration for a quick onset effect, and gastrointestinal toxicity has been observed in RA patients taking it. To solve these problems, we designed MLX solid nanop...